MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Akero Therapeutics Operating Income 2011-2026 | AKRO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Akero Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -285 M | -173 M | -115 M | -101 M | -80.2 M | -45.7 M | -13.8 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -13.8 M | -285 M | -116 M |
Quarterly Operating Income Akero Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -90.2 M | -80.9 M | - | -81.7 M | -65.7 M | - | -46.6 M | -35.6 M | -28.8 M | - | -36.1 M | - | -26.1 M | - | -24.4 M | -29 M | -15.1 M | - | -21.5 M | -16.5 M | -12.4 M | - | -16.3 M | -7.61 M | -5.51 M | - | -1.73 M | -8.66 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.73 M | -90.2 M | -32.5 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Apellis Pharmaceuticals
APLS
|
55.4 M | $ 20.22 | -2.32 % | $ 2.55 B |  USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 164.71 | -1.01 % | $ 8.19 B | USA |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.73 | -2.49 % | $ 1.11 B |  Canada |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
242 M | $ 8.5 | -2.63 % | $ 1.39 B | Britain |
 |
Catalyst Pharmaceuticals
CPRX
|
258 M | $ 23.88 | - | $ 2.92 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-23.4 M | $ 18.08 | 1.06 % | $ 868 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Certara
CERT
|
21 M | $ 7.19 | 1.93 % | $ 1.15 B | USA |
 |
Eton Pharmaceuticals
ETON
|
-1.19 M | $ 17.72 | -2.37 % | $ 454 M | USA |
 |
Exelixis
EXEL
|
872 M | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Galapagos NV
GLPG
|
-166 M | $ 33.13 | -2.82 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
-16 M | $ 27.7 | 1.12 % | $ 361 M | USA |
 |
Genmab A/S
GMAB
|
2.64 B | $ 27.67 | -6.69 % | $ 17.7 B |  Danmark |
 |
Capricor Therapeutics
CAPR
|
-24.1 M | $ 26.04 | -3.07 % | $ 697 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-58.5 M | $ 0.99 | -2.92 % | $ 72.7 M | USA |
 |
Halozyme Therapeutics
HALO
|
469 M | $ 69.39 | -0.67 % | $ 8.32 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
208 M | $ 28.56 | -1.19 % | $ 1.64 B | USA |
 |
ImmuCell Corporation
ICCC
|
-1.64 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Immuron Limited
IMRN
|
-2.87 M | $ 0.75 | -0.69 % | $ 6.43 M |  Australia |
 |
Immatics N.V.
IMTX
|
-86.3 M | $ 9.86 | -1.3 % | $ 620 M | Germany |
 |
Immunic
IMUX
|
-103 M | $ 1.1 | 3.3 % | $ 171 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Inhibrx
INBX
|
-219 M | $ 75.96 | -1.97 % | $ 3.58 B | USA |
 |
InMed Pharmaceuticals
INM
|
-7.95 M | $ 0.75 | -8.49 % | $ 1.84 M | Canada |
 |
INmune Bio
INMB
|
-29.7 M | $ 1.41 | 6.07 % | $ 25.4 M | USA |
 |
Insmed Incorporated
INSM
|
-1.25 B | $ 146.89 | 0.39 % | $ 29.2 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-160 M | $ 3.19 | -4.49 % | $ 1.14 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-47.8 M | $ 1.63 | -1.21 % | $ 235 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
Agios Pharmaceuticals
AGIO
|
-472 M | $ 29.11 | -0.31 % | $ 1.69 B | USA |